QIAGEN Added to NASDAQ-100 Index
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ VENLO, The Netherlands, December 14, 2009 - QIAGEN N.V. (NASDAQ:QGEN; Frankfurt, Prime Standard: QIA) today announced that its commonshares will be included in the NASDAQ-100 Index effective as of thestart of trading on December 21, 2009. The NASDAQ-100 Index comprisesthe top 100 non-financial securities listed on The NASDAQ StockMarket based on market capitalization. Launched in January 1985, theNASDAQ-100 Index includes companies across major industry groups."The addition of our securities to the NASDAQ-100 Index reflects ourstrong growth, consistent performance and significant valuecreation", said Peer M. Schatz, CEO of QIAGEN. "We are honoured to beadded to this elite set of companies". QIAGEN's common shares havebeen trading on The NASDAQ Stock Market since the Company's initialpublic offering on June 28, 1996.About QIAGEN:QIAGEN N.V., a Netherlands holding company, is theleading global provider of sample and assay technologies. Sampletechnologies are used to isolate and process DNA, RNA and proteinsfrom biological samples such as blood or tissue. Assay technologiesare used to make such isolated bio-molecules visible. QIAGEN hasdeveloped and markets more than 500 sample and assay products as wellas automated solutions for such consumables. The company provides itsproducts to molecular diagnostics laboratories, academic researchers,pharmaceutical and biotechnology companies, and appliedtesting customers for purposes such as forensics, animal or foodtesting and pharmaceutical process control. QIAGEN's assaytechnologies include one of the broadest panels of moleculardiagnostic tests available worldwide. This panel includes thedigeneHPV Test, which is regarded as a "gold standard" in testing forhigh-risk types of human papillomavirus (HPV), the primary cause ofcervical cancer, as well as a broad suite of solutions for infectiousdisease testing and companion diagnostics. QIAGEN employs more than3,400 people in over 30 locations worldwide. Further informationabout QIAGEN can be found at http://www.qiagen.com/.SAFE HARBOR STATEMENTStatements contained in this release that are not historical factsare forward-looking statements, including statements about ourproducts, markets, strategy and operating results. Such statementsare based on current expectations that involve risks anduncertainties including, but not limited to, those associated with:management of growth and international operations (including currencyfluctuations and logistics), variability of our operating results,commercial development of our markets (including applied testing,clinical and academic research, proteomics, women's health/HPVtesting, molecular diagnostics, personalized healthcare and companiondiagnostics), our relationships with customers, suppliers andstrategic partners, competition, changes in technology, fluctuationsin demand, regulatory requirements, identifying, developing andproducing integrated products differentiated from our competitors'products, market acceptance of our products, and integration ofacquired technologies and businesses. For further information, referto our filings with the SEC, including our latest Annual Report onForm 20-F. Information in this release is as of the date of therelease, and we undertake no duty to update this information unlessrequired by law. # # #Contacts:Investor Relations: Public Relations:Dr. Solveigh Mähler Dr. Thomas TheuringerDirector Investor Relations Associate Director PublicQIAGEN N.V. Relations+49 2103 29 11710 QIAGEN GmbHe-mail: +49-2103-29-11826solveigh.maehler(at)qiagen.com e-mail: thomas.theuringer(at)qiagen.comAlbert F. FleuryInvestor Relations North AmericaQIAGEN N.V.+1 301 944 7028e-mail: albert.fleury(at)qiagen.com --- End of Message ---Qiagen N.V.Spoorstraat 50 KJ Venlo NetherlandsWKN: 901626; ISIN: NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, TecDAX;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;
Datum: 14.12.2009 - 10:00 Uhr
Sprache: Deutsch
News-ID 9583
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 477 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"QIAGEN Added to NASDAQ-100 Index"
steht unter der journalistisch-redaktionellen Verantwortung von
Qiagen N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
